EMBC Key Statistics, Chart & Performance
The current stock price of EMBC is 12.67 USD. In the past month the price increased by 7.53%. In the past year, price decreased by -31.21%.
EMBC Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| COO | COOPER COS INC/THE | 19.79 | 16.25B | ||
| SOLV | SOLVENTUM CORP | 13.65 | 14.06B | ||
| ALGN | ALIGN TECHNOLOGY INC | 17.55 | 12.18B | ||
| MMSI | MERIT MEDICAL SYSTEMS INC | 21.92 | 4.84B | ||
| LNTH | LANTHEUS HOLDINGS INC | 10.86 | 4.29B | ||
| HAE | HAEMONETICS CORP/MASS | 16.63 | 3.74B | ||
| ICUI | ICU MEDICAL INC | 18.68 | 3.67B | ||
| XRAY | DENTSPLY SIRONA INC | 7.68 | 2.42B | ||
| NEOG | NEOGEN CORP | 31.91 | 2.01B | ||
| UFPT | UFP TECHNOLOGIES INC | 29.46 | 1.96B | ||
| STAA | STAAR SURGICAL CO | N/A | 1.10B | ||
| BVS | BIOVENTUS INC - A | 13.08 | 638.91M |
Related stock screener links
About EMBC
Company Profile
Embecta Corp. engages in the provision of medical devices used in the treatment of diabetes. The company is headquartered in Parsippany, New Jersey and currently employs 1,850 full-time employees. The company went IPO on 2022-03-21. The firm has a portfolio of marketed products, including a variety of pen needles, syringes and safety injection devices. Its pen needles are sterile, single-use, medical devices, designed to be used in conjunction with pen injectors that inject insulin or other diabetes medications. The company also sells safety pen needles, which have shields on both ends of the cannula that automatically deploy after the injection to help prevent needlestick exposure and injury during injection and disposal. Its traditional and safety pen needles are compatible and frequently used with pen injectors in the market. The company sells sterile, single-use insulin syringes, which are used to inject insulin drawn from insulin vials. The company also sells safety insulin syringes. The company distributes its products through a variety of channels, including retail, hospitals and pharmacies.
Company Info
EMBECTA CORP
300 Kimball Drive, Suite 300
Parsippany NEW JERSEY US
Employees: 2100
Phone: 18624010000
EMBECTA CORP / EMBC FAQ
What does EMBC do?
Embecta Corp. engages in the provision of medical devices used in the treatment of diabetes. The company is headquartered in Parsippany, New Jersey and currently employs 1,850 full-time employees. The company went IPO on 2022-03-21. The firm has a portfolio of marketed products, including a variety of pen needles, syringes and safety injection devices. Its pen needles are sterile, single-use, medical devices, designed to be used in conjunction with pen injectors that inject insulin or other diabetes medications. The company also sells safety pen needles, which have shields on both ends of the cannula that automatically deploy after the injection to help prevent needlestick exposure and injury during injection and disposal. Its traditional and safety pen needles are compatible and frequently used with pen injectors in the market. The company sells sterile, single-use insulin syringes, which are used to inject insulin drawn from insulin vials. The company also sells safety insulin syringes. The company distributes its products through a variety of channels, including retail, hospitals and pharmacies.
What is the current price of EMBC stock?
The current stock price of EMBC is 12.67 USD. The price decreased by -1.4% in the last trading session.
What is the dividend status of EMBECTA CORP?
EMBECTA CORP (EMBC) has a dividend yield of 4.7%. The yearly dividend amount is currently 0.6.
What is the ChartMill technical and fundamental rating of EMBC stock?
EMBC has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 6 out of 10.
What do analysts say about EMBECTA CORP (EMBC) stock?
9 analysts have analysed EMBC and the average price target is 17 USD. This implies a price increase of 34.18% is expected in the next year compared to the current price of 12.67.
What is the GICS sector and industry of EMBC stock?
EMBECTA CORP (EMBC) operates in the Health Care sector and the Health Care Equipment & Supplies industry.
Can you provide the growth outlook for EMBECTA CORP?
The Revenue of EMBECTA CORP (EMBC) is expected to decline by 0% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
EMBC Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to EMBC. When comparing the yearly performance of all stocks, EMBC is a bad performer in the overall market: 84.86% of all stocks are doing better.
EMBC Fundamental Analysis
ChartMill assigns a fundamental rating of 6 / 10 to EMBC. While EMBC belongs to the best of the industry regarding profitability, there are some minor concerns on its financial health.
EMBC Financial Highlights
Over the last trailing twelve months EMBC reported a non-GAAP Earnings per Share(EPS) of 2.97. The EPS increased by 20.24% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 8.83% | ||
| ROA | 8.75% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
EMBC Forecast & Estimates
9 analysts have analysed EMBC and the average price target is 17 USD. This implies a price increase of 34.18% is expected in the next year compared to the current price of 12.67.